Malaria vaccine trial endpoints - bridging the gaps between trial design, public health and the next generation of vaccines.
Publication
, Journal Article
O'Meara, WP; Lang, T
Published in: Parasite Immunol
September 2009
A recent working group convened by the World Health Organization recommended that time to first or only episode of clinical malaria should be used to evaluate vaccine efficacy in phase III trials. However, calculating vaccine efficacy based on this endpoint misses important aspects of malaria disease and transmission. Here, we discuss the gaps that this approach leaves in predicting the potential public health impact of a vaccine and the challenges faced by vaccine trial designers. We examine the implications of current vaccine trial design on effectiveness studies and the next generation of malaria vaccines.
Duke Scholars
Published In
Parasite Immunol
DOI
EISSN
1365-3024
Publication Date
September 2009
Volume
31
Issue
9
Start / End Page
574 / 581
Location
England
Related Subject Headings
- Treatment Outcome
- Research Design
- Mycology & Parasitology
- Malaria Vaccines
- Malaria
- Humans
- Clinical Trials, Phase III as Topic
- Biomarkers
- 3204 Immunology
- 3107 Microbiology
Citation
APA
Chicago
ICMJE
MLA
NLM
O’Meara, W. P., & Lang, T. (2009). Malaria vaccine trial endpoints - bridging the gaps between trial design, public health and the next generation of vaccines. Parasite Immunol, 31(9), 574–581. https://doi.org/10.1111/j.1365-3024.2009.01144.x
O’Meara, W. P., and T. Lang. “Malaria vaccine trial endpoints - bridging the gaps between trial design, public health and the next generation of vaccines.” Parasite Immunol 31, no. 9 (September 2009): 574–81. https://doi.org/10.1111/j.1365-3024.2009.01144.x.
O’Meara WP, Lang T. Malaria vaccine trial endpoints - bridging the gaps between trial design, public health and the next generation of vaccines. Parasite Immunol. 2009 Sep;31(9):574–81.
O’Meara, W. P., and T. Lang. “Malaria vaccine trial endpoints - bridging the gaps between trial design, public health and the next generation of vaccines.” Parasite Immunol, vol. 31, no. 9, Sept. 2009, pp. 574–81. Pubmed, doi:10.1111/j.1365-3024.2009.01144.x.
O’Meara WP, Lang T. Malaria vaccine trial endpoints - bridging the gaps between trial design, public health and the next generation of vaccines. Parasite Immunol. 2009 Sep;31(9):574–581.
Published In
Parasite Immunol
DOI
EISSN
1365-3024
Publication Date
September 2009
Volume
31
Issue
9
Start / End Page
574 / 581
Location
England
Related Subject Headings
- Treatment Outcome
- Research Design
- Mycology & Parasitology
- Malaria Vaccines
- Malaria
- Humans
- Clinical Trials, Phase III as Topic
- Biomarkers
- 3204 Immunology
- 3107 Microbiology